Pharma BD Deal Intelligence
Hoechst AG's $7.1B all-cash acquisition of Marion Merrell Dow's remaining shares handed the German conglomerate full control of Cardizem and Seldane, creating Hoechst Marion Roussel. The structured two-step buyout—first Dow Chemical's 71% stake, then the public float at $25.75/share—consolidated a fragmented ownership base into a single US commercial platform.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Hoechst AG agreed to acquire Marion Merrell Dow for $7.1 billion, purchasing all outstanding shares at $25.75 per share, creating Hoechst Marion Roussel with…
The Federal Trade Commission reviewed Hoechst AG's $7.1 billion acquisition of Marion Merrell Dow, requiring divestitures to restore competition for four drugs…
Source summaries from our enrichment pipeline; follow links for originals.
All 3 sources with sentiment breakdown →
Hoechst AG acquired the remaining shares of Marion Merrell Dow it did not already own for $7.1 billion ($25.75/share). The deal was structured in two steps: first acquiring Dow Chemical's 71% stake (~$5.1B), then the remaining public float. The combined entity became Hoechst Marion Roussel.
50M US cases/yr · $15.0B US Cardiovascular Rx Market (1995)
Hypertension affects ~48.1% of US adults (~119.9M people; CDC), contributing to ~664,470 deaths in 2023 and driving angina, MI, stroke, and heart failure. Only ~1 in 4 hypertensive adults are controlled. Calcium channel blockers such as diltiazem (Cardizem) reduce vascular smooth muscle tone and cardiac contractility, serving as a core guideline option alongside ACE inhibitors, ARBs, and thiazides.
The acquisition came as Marion Merrell Dow faced significant headwinds: Cardizem was losing patent protection and Seldane (terfenadine), the first non-sedating antihistamine, was under safety scrutiny for cardiac arrhythmias and was ultimately withdrawn in 1998. The combined entity became Hoechst Marion Roussel before Hoechst merged with Rhone-Poulenc to form Aventis in 1999.
FTC approved after Hoechst agreed to divest drugs in four overlapping classes. Regulatory step in Hoechst AG's acquisition process for Marion Merrell Dow Inc..
Hoechst AG acquired Dow 71% stake in Marion Merrell Dow at $25.75/share for $7.1B, creating Hoechst Marion Roussel.
Combined entity had $10B+ annual sales, ranking among top five global pharma companies.
HMR absorbed into Aventis; later combined with Sanofi-Synthelabo in 2004 to form Sanofi-Aventis.
Successful Consolidation Play. Assessment of Hoechst AG's $7.1B acquisition of Marion Merrell Dow Inc. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hoechst AG / Marion Merrell Dow Inc. (this deal) | 1995 | $7.1B | 73 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 1995 deals · Cardiovascular deals